Novel role of VMP1 as modifier of the pancreatic tumor cell response to chemotherapeutic drugs

Marine Gilabert, Maria Inés Vaccaro, Martin E Fernandez-Zapico, Ezequiel L. Calvo, Olivier Turrini, Véronique Secq, Stéphane Garcia, Vincent Moutardier, Gwen Lomberk, Nelson Dusetti, Raul Urrutia, Juan L. Iovanna

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

We hypothesized that inhibiting molecules that mediate the adaptation response to cellular stress can antagonize the resistance of pancreatic cancer cells to chemotherapeutic drugs. Toward this end, here, we investigated how VMP1, a stress-induced autophagy-associated protein, modulate stress responses triggered by chemotherapeutic agents in PDAC. We find that VMP1 is particularly over-expressed in poorly differentiated human pancreatic cancer. Pharmacological studies show that drugs that work, in part, via the endoplasmic reticulum stress response, induce VMP1 expression. Similarly, VMP1 is induced by known endoplasmic reticulum stress activators. Genetic inactivation of VMP1 using RNAi-based antagonize the pancreatic cancer stress response to antitumoral agents. Functionally, we find that VMP1 regulates both autophagy and chemotherapeutic resistance even in the presence of chloroquin, ATG5 or Beclin 1 siRNAs, or a Beclin 1-binding VMP1 mutant. In addition, VMP1 modulates endoplasmic reticulum stress independently of its coupling to the molecular and cellular autophagy machinery. Preclinical studies demonstrate that xenografts expressing an inducible and tractable form of VMP1 show increased resistance to the gemcitabine treatment. These results underscore a novel role for VMP1 as a potential therapeutic target for combinatorial therapies aimed at sensitizing pancreatic cancer cells to chemotherapeutic agents as well as provide novel molecular mechanisms to better understand this phenomenon.

Original languageEnglish (US)
Pages (from-to)1834-1843
Number of pages10
JournalJournal of Cellular Physiology
Volume228
Issue number9
DOIs
StatePublished - Sep 2013

Fingerprint

Pancreatic Neoplasms
Endoplasmic Reticulum Stress
Tumors
Autophagy
Cells
gemcitabine
Pharmaceutical Preparations
Neoplasms
Chloroquine
Heat-Shock Proteins
RNA Interference
Heterografts
Machinery
Pharmacology
Molecules
Therapeutics
Beclin-1

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Cell Biology
  • Physiology

Cite this

Novel role of VMP1 as modifier of the pancreatic tumor cell response to chemotherapeutic drugs. / Gilabert, Marine; Vaccaro, Maria Inés; Fernandez-Zapico, Martin E; Calvo, Ezequiel L.; Turrini, Olivier; Secq, Véronique; Garcia, Stéphane; Moutardier, Vincent; Lomberk, Gwen; Dusetti, Nelson; Urrutia, Raul; Iovanna, Juan L.

In: Journal of Cellular Physiology, Vol. 228, No. 9, 09.2013, p. 1834-1843.

Research output: Contribution to journalArticle

Gilabert, M, Vaccaro, MI, Fernandez-Zapico, ME, Calvo, EL, Turrini, O, Secq, V, Garcia, S, Moutardier, V, Lomberk, G, Dusetti, N, Urrutia, R & Iovanna, JL 2013, 'Novel role of VMP1 as modifier of the pancreatic tumor cell response to chemotherapeutic drugs', Journal of Cellular Physiology, vol. 228, no. 9, pp. 1834-1843. https://doi.org/10.1002/jcp.24343
Gilabert, Marine ; Vaccaro, Maria Inés ; Fernandez-Zapico, Martin E ; Calvo, Ezequiel L. ; Turrini, Olivier ; Secq, Véronique ; Garcia, Stéphane ; Moutardier, Vincent ; Lomberk, Gwen ; Dusetti, Nelson ; Urrutia, Raul ; Iovanna, Juan L. / Novel role of VMP1 as modifier of the pancreatic tumor cell response to chemotherapeutic drugs. In: Journal of Cellular Physiology. 2013 ; Vol. 228, No. 9. pp. 1834-1843.
@article{3b2a8d07082642fdbc08dd799281b085,
title = "Novel role of VMP1 as modifier of the pancreatic tumor cell response to chemotherapeutic drugs",
abstract = "We hypothesized that inhibiting molecules that mediate the adaptation response to cellular stress can antagonize the resistance of pancreatic cancer cells to chemotherapeutic drugs. Toward this end, here, we investigated how VMP1, a stress-induced autophagy-associated protein, modulate stress responses triggered by chemotherapeutic agents in PDAC. We find that VMP1 is particularly over-expressed in poorly differentiated human pancreatic cancer. Pharmacological studies show that drugs that work, in part, via the endoplasmic reticulum stress response, induce VMP1 expression. Similarly, VMP1 is induced by known endoplasmic reticulum stress activators. Genetic inactivation of VMP1 using RNAi-based antagonize the pancreatic cancer stress response to antitumoral agents. Functionally, we find that VMP1 regulates both autophagy and chemotherapeutic resistance even in the presence of chloroquin, ATG5 or Beclin 1 siRNAs, or a Beclin 1-binding VMP1 mutant. In addition, VMP1 modulates endoplasmic reticulum stress independently of its coupling to the molecular and cellular autophagy machinery. Preclinical studies demonstrate that xenografts expressing an inducible and tractable form of VMP1 show increased resistance to the gemcitabine treatment. These results underscore a novel role for VMP1 as a potential therapeutic target for combinatorial therapies aimed at sensitizing pancreatic cancer cells to chemotherapeutic agents as well as provide novel molecular mechanisms to better understand this phenomenon.",
author = "Marine Gilabert and Vaccaro, {Maria In{\'e}s} and Fernandez-Zapico, {Martin E} and Calvo, {Ezequiel L.} and Olivier Turrini and V{\'e}ronique Secq and St{\'e}phane Garcia and Vincent Moutardier and Gwen Lomberk and Nelson Dusetti and Raul Urrutia and Iovanna, {Juan L.}",
year = "2013",
month = "9",
doi = "10.1002/jcp.24343",
language = "English (US)",
volume = "228",
pages = "1834--1843",
journal = "Journal of Cellular Physiology",
issn = "0021-9541",
publisher = "Wiley-Liss Inc.",
number = "9",

}

TY - JOUR

T1 - Novel role of VMP1 as modifier of the pancreatic tumor cell response to chemotherapeutic drugs

AU - Gilabert, Marine

AU - Vaccaro, Maria Inés

AU - Fernandez-Zapico, Martin E

AU - Calvo, Ezequiel L.

AU - Turrini, Olivier

AU - Secq, Véronique

AU - Garcia, Stéphane

AU - Moutardier, Vincent

AU - Lomberk, Gwen

AU - Dusetti, Nelson

AU - Urrutia, Raul

AU - Iovanna, Juan L.

PY - 2013/9

Y1 - 2013/9

N2 - We hypothesized that inhibiting molecules that mediate the adaptation response to cellular stress can antagonize the resistance of pancreatic cancer cells to chemotherapeutic drugs. Toward this end, here, we investigated how VMP1, a stress-induced autophagy-associated protein, modulate stress responses triggered by chemotherapeutic agents in PDAC. We find that VMP1 is particularly over-expressed in poorly differentiated human pancreatic cancer. Pharmacological studies show that drugs that work, in part, via the endoplasmic reticulum stress response, induce VMP1 expression. Similarly, VMP1 is induced by known endoplasmic reticulum stress activators. Genetic inactivation of VMP1 using RNAi-based antagonize the pancreatic cancer stress response to antitumoral agents. Functionally, we find that VMP1 regulates both autophagy and chemotherapeutic resistance even in the presence of chloroquin, ATG5 or Beclin 1 siRNAs, or a Beclin 1-binding VMP1 mutant. In addition, VMP1 modulates endoplasmic reticulum stress independently of its coupling to the molecular and cellular autophagy machinery. Preclinical studies demonstrate that xenografts expressing an inducible and tractable form of VMP1 show increased resistance to the gemcitabine treatment. These results underscore a novel role for VMP1 as a potential therapeutic target for combinatorial therapies aimed at sensitizing pancreatic cancer cells to chemotherapeutic agents as well as provide novel molecular mechanisms to better understand this phenomenon.

AB - We hypothesized that inhibiting molecules that mediate the adaptation response to cellular stress can antagonize the resistance of pancreatic cancer cells to chemotherapeutic drugs. Toward this end, here, we investigated how VMP1, a stress-induced autophagy-associated protein, modulate stress responses triggered by chemotherapeutic agents in PDAC. We find that VMP1 is particularly over-expressed in poorly differentiated human pancreatic cancer. Pharmacological studies show that drugs that work, in part, via the endoplasmic reticulum stress response, induce VMP1 expression. Similarly, VMP1 is induced by known endoplasmic reticulum stress activators. Genetic inactivation of VMP1 using RNAi-based antagonize the pancreatic cancer stress response to antitumoral agents. Functionally, we find that VMP1 regulates both autophagy and chemotherapeutic resistance even in the presence of chloroquin, ATG5 or Beclin 1 siRNAs, or a Beclin 1-binding VMP1 mutant. In addition, VMP1 modulates endoplasmic reticulum stress independently of its coupling to the molecular and cellular autophagy machinery. Preclinical studies demonstrate that xenografts expressing an inducible and tractable form of VMP1 show increased resistance to the gemcitabine treatment. These results underscore a novel role for VMP1 as a potential therapeutic target for combinatorial therapies aimed at sensitizing pancreatic cancer cells to chemotherapeutic agents as well as provide novel molecular mechanisms to better understand this phenomenon.

UR - http://www.scopus.com/inward/record.url?scp=84878217099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878217099&partnerID=8YFLogxK

U2 - 10.1002/jcp.24343

DO - 10.1002/jcp.24343

M3 - Article

VL - 228

SP - 1834

EP - 1843

JO - Journal of Cellular Physiology

JF - Journal of Cellular Physiology

SN - 0021-9541

IS - 9

ER -